Table 1 Baseline study characteristics, overall and stratified by hepatitis C virus co-infection
|  | Overall (n = 2595) | HCV positive (n = 484) | HCV negative (n = 1978) | Unknown (n = 133) |
|---|---|---|---|---|
Median age (IQR), years | 40 (33, 46) | 41 (35, 47) | 39 (33, 46) | 41 (36, 49) |
Male sex | 2195 (85%) | 394 (81%) | 1690 (85%) | 111 (83%) |
African/Caribbean ethnicity a | 368 (24%) | 17 (5%) | 344 (29%) | 17 (27%) |
Median eGFR (IQR), mL/min/1.73Â m2 | 105 (92, 116) | 103 (91, 114) | 105 (92, 117) | 106 (96, 115) |
Injection drug use as HIV risk factor b | 389 (18%) | 302 (69%) | 83 (5%) | 4 (4%) |
Median CD4+ cell count (IQR), cells/μL | 210 (102, 318) | 190 (80, 290) | 220 (110, 323) | 200 (100, 319) |
Median HIV viral load (IQR), log10 copies/mL | 4.9 (4.4, 5.2) | 4.9 (4.4, 5.1) | 4.9 (4.4, 5.2) | 4.9 (4.4, 5.2) |
Previous AIDS-defining event c | 450 (19%) | 99 (22%) | 331 (19%) | 20 (18%) |
Tenofovir use | 1410 (54%) | 227 (47%) | 1111 (56%) | 72 (54%) |
Atazanavir use | 666 (26%) | 144 (30%) | 494 (25%) | 28 (21%) |
Lopinavir use | 471 (18%) | 99 (20%) | 347 (18%) | 25 (19%) |
Median year of cART initiation (IQR) | 2007 (2004, 2009) | 2006 (2003, 2009) | 2008 (2004, 2009) | 2008 (2004, 2010) |
Liver fibrosis (APRI ≥1.5) d | 145 (7%) | 69 (17%) | 71 (5%) | 5 (6%) |
Diabetes e | 119 (5%) | 26 (6%) | 89 (5%) | 4 (3%) |
Hypertension f | 74 (12%) | 13 (15%) | 59 (12%) | 2 (8%) |
Cohort province | ||||
 British Columbia | 1103 (43%) | 307 (63%) | 738 (37%) | 58 (44%) |
 Ontario | 838 (32%) | 110 (23%) | 694 (35%) | 34 (26%) |
 Québec | 654 (25%) | 67 (14%) | 546 (28%) | 41 (31%) |